Drugs / Licensed RSV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06686654 | Nov 2024 → Jan 2027 expected | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06481579 Comparator | Jun → Jul 2024 | — | Icosavax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Licensed RSV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481579 ↗ |
| Modality | Vaccine | “Licensed RSV Vaccine” NCT06481579 ↗ |
| Route | Intramuscular | “Licensed RSV Vaccine (AREXVY) IM injection.” NCT06481579 ↗ |